Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BNA 2023 | Three-month outcomes for patients with chronic pain using cannabis-based medical products

Anne Schlag, PhD, Drug Science, London, UK, shares real-world registry data from patients using cannabis-based medical products for chronic pain, after 3-months of use. The registry, Project T21, aims to advance scientific evidence on medical cannabis and has enrolled over 3,500 patients using cannabis-based medical products for a range of conditions. Chronic pain was the most commonly reported reason for medical cannabis use and initial baseline data revealed low general health scores among these participants. However, 3-month data from 618 patients demonstrated significant improvements across general health, quality of life, mood, and sleep quality. Notably, both pain intensity and pain interference were significantly decreased. Dr Schlag also highlighted a trend towards reduction in opioid use in this population. Among the 350 patients who reported opiod use, the average morphine milligram equivalent (MME), a common metric for opioid dosage, fell from 45mg/day at baseline to 19mg/day at 3 months. Further analysis is ongoing, as research continues to explore the implications and intricacies of the data. This interview took place at The BNA 2023 International Festival of Neuroscience in Brighton, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Anne Schlag reports the following disclosures:
SAB at Chilam; Somai; PsychCapital
Honorary roles: Trustee Intractable
Drug Science receives an unrestricted educational grant from a consortium of medical cannabis companies to further its mission, that is the pursuit of an unbiased and scientific assessment of drugs regardless of their regulatory class.